Accelerating personalised medicine – How the pandemic is driving innovation in bioprocessing

Personalised medicines use advances in genetics and bioinformatics to target specific patient groups and treat previously untreatable diseases. These small patient groups and novel medicinal products result in new challenges for the bioprocessing industry.

Find out about the challenges of manufacturing personalised medicines and the lessons being learned from the pandemic with personalised medicine and vaccine-producer Oxford Biomedica, Franz Ziel and Watson-Marlow Fluid Technology Group.

Find out more and register here